Nabriva Therapeutics submits new drug applications to U.S. FDA for intravenous and oral lefamulin to treat community-acquired bacterial pneumonia in adults

20 December 2018 - Nabriva Therapeutics announced the submission of two new drug applications to the U.S. FDA for the ...

Read more →

AbbVie submits new drug application to U.S. FDA and marketing authorisation application to EMA for upadacitinib for treatment of adults with moderate to severe rheumatoid arthritis

20 December 2018 - Regulatory applications supported by robust SELECT Phase 3 program evaluating more than 4,000 patients with moderate to ...

Read more →

Pharmaxis announces resubmission of Bronchitol NDA in USA

18 December 2018 - Pharmaxis today announced the resubmission of the Bronchitol new drug application with the United States FDA ...

Read more →

ADMA Biologics provides regulatory update on Bivigam PAS submissions

19 December 2018 - FDA issues complete response letter for drug substance, approves supplement for drug product. ...

Read more →

Chugai's satralizumab receives FDA breakthrough therapy designation for neuromyelitis optica and neuromyelitis optica spectrum disorders

19 December 2018 - Designation is seventh for Chugai originated drug. ...

Read more →

FDA approves new indication for Envarsus XR (tacrolimus extended-release tablets)

19 December 2018 - Veloxis Pharmaceuticals announced today that the U.S. FDA approved a new indication for Envarsus XR (tacrolimus ...

Read more →

FDA approves Merck’s Keytruda (pembrolizumab) for the treatment of adult and paediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, a rare form of skin cancer

19 December 2018 - Accelerated approval based on results of CITN-09/KEYNOTE-017, where Keytruda monotherapy demonstrated an objective response rate of 56%. ...

Read more →

DBV Technologies provides update on Viaskin Peanut for children four to 11 years of age

19 December 2018 - Application withdrawn following discussions with FDA regarding insufficient data on manufacturing procedures and quality controls. ...

Read more →

Lynparza approved by US FDA for first-line maintenance therapy in BRCA-mutated advanced ovarian cancer

19 December 2018 - AstraZeneca and MSD’s Lynparza reduced the risk of disease progression or death by 70% compared to placebo ...

Read more →

More lawsuits = higher drug prices

18 December 2018 - The FDA pulls an Obama rule that was a trial-lawyer special. ...

Read more →

Equillium granted U.S. FDA fast track designation for EQ001 for the treatment of acute graft-versus-host disease

19 December 2018 - Company plans to initiate Phase 1b/2 EQUATE clinical trial in early 2019. ...

Read more →

FDA advances new scientific framework to promote greater predictability, efficiency in oncology drug development

19 December 2018 - Today, the U.S. FDA issued guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and ...

Read more →

Comparative assessment of clinical benefit using the ESMO Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework Net Health Benefit Score

19 December 2018 - To better understand the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) ...

Read more →

Establishing the effectiveness of procedural interventions: the limited role of randomised trials

18 December 2018 - Procedural interventions comprise a large and growing component of medical care. Patients, physicians, health care organisations, and ...

Read more →

Warren unveils bill to lower drug prices by letting government manufacture them

18 December 2018 - Senator Elizabeth Warren has unveiled a bill aimed at lowering drug prices by allowing the government ...

Read more →